Results 1 to 10 of about 355,709 (346)
Asian Pacific Journal of Cancer Biology, 2021 Introduction: The preferred first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive (EGFRm) advanced/metastatic non-small lung cancer (NSCLC) are EGFR-tyrosine kinase inhibitors (TKIs).
Jae Cheol Lee +10 more
doaj +1 more source
Immunotherapeutic Advances for NSCLC
Biologics: Targets and Therapy, 2021 Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer (NSCLC) patients without oncogenic driver alterations. These agents, namely immune checkpoint inhibitors (ICIs), have also widely demonstrated a remarkable efficacy in locally ...
Massafra, Marco +8 more
openaire +5 more sources
Frontiers in Oncology, 2022 Laminin is an extracellular matrix multidomain trimeric glycoprotein, that has a potential role in tumor progression. Here, we studied the effects of non-small cell lung cancer (NSCLC) cells interaction on laminin and explored the underlying mechanism of
Xiaopeng Zhao +6 more
doaj +1 more source
Focus on Nivolumab in NSCLC [PDF]
Frontiers in Medicine, 2016 Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues.
Cortinovis D. L. +4 more
openaire +4 more sources
Lung Cancer: Targets and Therapy, 2021 State-of-the-art cancer precision medicine approaches involve targeted inactivation of chemically and immunologically addressable vulnerabilities that often yield impressive initial anti-tumor responses in patients. Nonetheless, these responses are overshadowed by therapy resistance that follows. AXL, a receptor tyrosine kinase with bona fide oncogenic
Aubhishek Zaman, Trever G. Bivona
openaire +4 more sources
Cancers, 2023 Non-small cell lung cancer (NSCLC) is still one of the leading causes of death worldwide. This is mostly because the majority of lung cancers are discovered in advanced stages. In the era of conventional chemotherapy, the prognosis of advanced NSCLC was grim. Important results have been reported in thoracic oncology since the discovery of new molecular
Cannone, Giorgio +7 more
openaire +3 more sources
Фармакоэкономика, 2023 Objective: to evaluate the clinical and economic effectiveness of alectinib in comparison with lorlatinib in adult patients with advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).Materials and methods. The calculations
A. S. Kolbin +3 more
doaj +1 more source
Frontiers in Oncology, 2012 The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of intracellular lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides. PI3K regulate signaling pathways for neoplasia, including cell proliferation, adhesion, survival, and motility.
Enriqueta Felip, Alex Martinez-Marti
openaire +3 more sources
Сибирский онкологический журнал, 2023 Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and methods ...
D. I. Yudin +4 more
doaj +1 more source